Robert Wood, MD

Robert Wood, MD, of Johns Hopkins University explains what the July 31 exit means for peanut oral immunotherapy and omalizumab-assisted desensitization.

As Palforzia exits the market on July 31, 2026, allergists Robert Wood, MD, and Jacqueline Ross, MD, outline what changes for patients already in treatment.

Robert. Wood, MD, discusses post hoc OUTMATCH stage 2 findings on age and maintenance dosing in multiallergen oral immunotherapy.

Robert Wood, MD, discusses OUTMATCH data showing omalizumab beat multiallergen oral immunotherapy, though MOIT dropouts narrowed the gap.

Wood discussed the potential of BTK inhibition for peanut allergy and beyond.

Wood discussed factors that go into shared decision making for multi-food allergy.

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.